| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-109 |
Sentence |
denotes |
Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis. |
| T2 |
110-244 |
Sentence |
denotes |
Recent studies suggest that growth inhibition by 1,25-dihydroxyvitamin D3 represents an innovative approach to ovarian cancer therapy. |
| T3 |
245-432 |
Sentence |
denotes |
To understand the molecular mechanism of 1,25-dihydroxyvitamin D3 action, we profiled the hormone-induced changes in the transcriptome of ovarian cancer cells using microarray technology. |
| T4 |
433-513 |
Sentence |
denotes |
More than 200 genes were identified to be regulated by 1,25-dihydroxyvitamin D3. |
| T5 |
514-851 |
Sentence |
denotes |
Reverse transcription-PCR analyses confirmed the regulation of a group of apoptosis-related genes, including the up-regulation of the decoy receptor that inhibits tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) action, TRAIL receptor 4, and the down-regulation of Fas, the receptor that mediates the action of Fas ligand. |
| T6 |
852-910 |
Sentence |
denotes |
The regulation was further confirmed at the protein level. |
| T7 |
911-1061 |
Sentence |
denotes |
Consistent with the regulation of the death receptors, pretreatment with 1,25-dihydroxyvitamin D3 decreased apoptosis induced by TRAIL and Fas ligand. |
| T8 |
1062-1250 |
Sentence |
denotes |
Because persistent 1,25-dihydroxyvitamin D3 treatment has been shown to induce apoptosis in ovarian cancer, the hormone appears to exert a dual effect on the death of ovarian cancer cells. |
| T9 |
1251-1564 |
Sentence |
denotes |
Knockdown of TRAIL receptor 4 by RNA interference or ectopic expression of Fas relieved the suppressive effect of 1,25-dihydroxyvitamin D3, showing that molecular manipulation of death receptors is a viable approach to overcome the protective effect of 1,25-dihydroxyvitamin D3 on the apoptosis of ovarian cancer. |
| T10 |
1565-1792 |
Sentence |
denotes |
These strategies may allow ovarian cancer patients to benefit from therapy with both 1,25-dihydroxyvitamin D3 and ligands for death receptors, such as TRAIL, shown to selectively induce apoptosis in cancer but not normal cells. |
